KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer

BACKGROUND: KRAS mutations are predictive markers for the efficacy of anti-EGFR antibody therapies in patients with metastatic colorectal cancer. Although the mutational status of KRAS is reportedly highly concordant between primary and metastatic lesions, it is not yet clear whether genotoxic chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawamoto, Y, Tsuchihara, K, Yoshino, T, Ogasawara, N, Kojima, M, Takahashi, M, Ochiai, A, Bando, H, Fuse, N, Tahara, M, Doi, T, Esumi, H, Komatsu, Y, Ohtsu, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394966/
https://www.ncbi.nlm.nih.gov/pubmed/22617127
http://dx.doi.org/10.1038/bjc.2012.218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394966/
https://www.ncbi.nlm.nih.gov/pubmed/22617127
http://dx.doi.org/10.1038/bjc.2012.218

Ejemplares similares